The scoping study results for Nicanda Hill would see a payback period within less than 12 months and projected strong NPV and IRR results for developing a low cost, high quality graphite mine for arguably the largest known graphite project.
Imugene is an immuno-oncology company developing B-cell based immunotherapies. Immunotherapy has become one of the hottest and most promising areas of study for the treatment of a variety of cancerous tumours. Pfizer and Merck will JV on up to 20 preclinical immuno-oncology programs in 2015.
South Boulder's Colluli project is located in close proximity to the coast and is geographically favourable relative to key markets than its peers. Pre-feasibility completion is planned for February 2015 and DFS by mid 2015. Potential for offtake exists with Hong Kong based KLID.
U.S. stocks came under pressure Tuesday after a mixed bag of economic reports, including a disappointing consumer confidence report for November. Gold edged higher while WTI crude hit a four-year low. The ASX SPI 200 is up six points to 5356.
The major miners weighed on the broader Australian market today, but Medibank Private was the stock investors were watching, which delivered retail investors a 7% one-day gain but instos a one cent loss by the close.
MZI Resources has signed a pivotal sales agreement for its Keysbrook Mineral Sands Project with DuPont - the world’s largest titanium dioxide pigment producer. This significantly de-risks the project as well as provide revenue upon commencement of the agreement.
Proteomics International Laboratories has generated $7.5M in revenues since 2001 and does not intend using its resources to develop diagnostic tools or drugs, but seeks to licence the discovered IP to major pharma groups, who have the required resources for development.
Zinc has been a strong performer in 2014, with predictions of the best to come in 2015. The scale of drilling at Citronen has been impressive.
Apart from making significant cost reductions, Regeneus is in discussions with potential partners about licensing, development and distribution of its allogeneic stem cell products CryoShot and Progenza.
Apollo's shares are expected to lift after the latest intersection of iron-titanium-phosphate at Titan. Drill intersections and supporting geophysics suggest potential for large mineralised zones within both the Boulder and Claypan prospects.
These results are a significant step forward for Skyfall and the Magnetic End Use Rare Earth District. Spectrum is aiming to produce its first Rare Earth Oxide Product by reducing the oxalate component with results expected in weeks.
The metallurgical sampling will assist to optimise heap leach metallurgical and process design flow sheets for the Tarcoola. In turn this will assist in determining feasibility level capital and operating cost estimates for detailed evaluation of the project’s economics.